Who are Doravirine/Lamivudine/Tenofovir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Emtricitabine / Tenofovir, CAR, Truvada Pill, 3TC, tenofovir disproxil fumarate/emtricitabine, dolutegravir/abacavir/lamivudine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doravirine-lamivudine-tenofovir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Doravirine/Lamivudine/Tenofovir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doravirine/Lamivudine/Tenofovir (Doravirine/Lamivudine/Tenofovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NNRTI + NRTI + NtRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (NNRTI + NRTI + NtRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Doravirine/Lamivudine/Tenofovir (Doravirine/Lamivudine/Tenofovir) — Thomas Jefferson University. This fixed-dose combination inhibits HIV reverse transcriptase and integrase to block viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Doravirine/Lamivudine/Tenofovir TARGET	Doravirine/Lamivudine/Tenofovir	Thomas Jefferson University	phase 3	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase
Emtricitabine / Tenofovir	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
Truvada Pill	Truvada Pill	University of North Carolina, Chapel Hill	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
3TC	3TC	Avexa	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; hepatitis B polymerase
tenofovir disproxil fumarate/emtricitabine	tenofovir disproxil fumarate/emtricitabine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NNRTI + NRTI + NtRTI) class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Thomas Jefferson University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doravirine/Lamivudine/Tenofovir — Competitive Intelligence Brief. https://druglandscape.com/ci/doravirine-lamivudine-tenofovir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab